Global Insulin Glargine Market by Manufacturers, Regions, Type and Application, Forecast to 2021

Insulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).

Published by: GIR (GlobalInfoResearch)

Catalog: Biotechnology

Publishing Date: Oct 2016

Single User License: USD 3480

Corporate Users License: USD 4680

Delivery time: 24 hours

Pages: 114

Tables and Figures: 134

Full information ：[url]http://www.globalinforesearch.com/goods.php?id=1253[url]

Scope of the Report:

This report focuses on the Insulin Glargine in Global market, especially in North America, Europe and Asia-Pacific, Latin America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers

Sanofi-Aventis

Ganlee

Biocon

Market Segment by Regions, regional analysis covers

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

Latin America, Middle East and Africa

Market Segment by Type, covers

Single Dose Vial

Pre-filled Syringe

Market Segment by Applications, can be divided into

Treat type 1 diabetes

Treat type 2 diabetes

There are 13 Chapters to deeply display the global Insulin Glargine market.

Chapter 1, to describe Insulin Glargine Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Insulin Glargine, with sales, revenue, and price of Insulin Glargine, in 2015 and 2016;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016;

Chapter 4, to show...